Subtopic Deep Dive
TSC Diagnostic Criteria and Consensus
Research Guide
What is TSC Diagnostic Criteria and Consensus?
TSC Diagnostic Criteria and Consensus refers to standardized clinical and genetic guidelines established by international expert panels for diagnosing Tuberous Sclerosis Complex, updated periodically to incorporate advances in imaging, genetics, and minor feature recognition.
The 2012 International Tuberous Sclerosis Complex Consensus Conference established definitive diagnostic criteria, including major features like cortical tubers and subependymal nodules, with 1465 citations (Northrup et al., 2013). These were updated in 2021 to refine genetic testing requirements and surveillance recommendations, garnering 630 citations (Northrup et al., 2021). Over 20 consensus papers and guidelines shape current practice, emphasizing early detection in sporadic cases.
Why It Matters
Updated TSC diagnostic criteria improve case ascertainment for clinical trials, as seen in everolimus studies for epilepsy where precise diagnosis ensured eligibility (Krueger et al., 2013, 380 citations). They enable surveillance protocols reducing complications like subependymal giant cell astrocytoma progression (Krueger et al., 2013, 209 citations). Refined criteria via genetic insights from mosaic mutations aid familial screening and population studies like TOSCA, involving 2093 patients (Kingswood et al., 2017, 265 citations).
Key Research Challenges
Detecting Mosaic Mutations
Conventional testing misses 10-15% of TSC cases due to low-level mosaic or intronic mutations in TSC1/TSC2. Deep sequencing identifies these in most no-mutation-identified patients (Tyburczy et al., 2015, 286 citations). Updating criteria to include such variants remains challenging for clinical labs.
Validating Minor Criteria
Distinguishing minor diagnostic features like confetti skin lesions from mimics requires refined imaging and histology. Consensus updates incorporate these but lack standardized quantification (Northrup et al., 2021, 630 citations). Validation across diverse populations is limited.
Integrating Genetic Testing
Balancing clinical versus genetic diagnosis in sporadic cases complicates early detection. 2012 and 2021 criteria adjust thresholds, but accessibility and interpretation vary (Northrup et al., 2013, 1465 citations; Northrup et al., 2021).
Essential Papers
Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
Hope Northrup, Darcy A. Krueger, Hope Northrup et al. · 2013 · Pediatric Neurology · 1.5K citations
Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
Darcy A. Krueger, Hope Northrup, Hope Northrup et al. · 2013 · Pediatric Neurology · 832 citations
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
Hope Northrup, Mary E. Aronow, E. Martina Bebin et al. · 2021 · Pediatric Neurology · 630 citations
Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
Darcy A. Krueger, Angus A. Wilfong, Katherine Holland‐Bouley et al. · 2013 · Annals of Neurology · 380 citations
Objective Epilepsy is a major manifestation of tuberous sclerosis complex (TSC). Everolimus is an mammalian target of rapamycin complex 1 inhibitor with demonstrated benefit in several aspects of T...
Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing
Magdalena E. Tyburczy, Kira A. Dies, Jennifer Glass et al. · 2015 · PLoS Genetics · 286 citations
Tuberous sclerosis complex (TSC) is an autosomal dominant tumor suppressor gene syndrome due to germline mutations in either TSC1 or TSC2. 10-15% of TSC individuals have no mutation identified (NMI...
TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients
J.C. Kingswood, Guillaume Beaure d’Augères, Elena Belousova et al. · 2017 · Orphanet Journal of Rare Diseases · 265 citations
TOSCA is the largest clinical case series of TSC to date. It provided a detailed description of the disease trajectory with increased awareness of various TSC manifestations. The rates of different...
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Kim M. Keppler‐Noreuil, Victoria Parker, Thomas N. Darling et al. · 2016 · American Journal of Medical Genetics Part C Seminars in Medical Genetics · 254 citations
The phosphatidylinositol‐3‐kinase (PI3K)/AKT/mTOR signaling pathway plays an essential role in regulation of normal cell growth, metabolism, and survival. Somatic activating mutations in the PI3K/A...
Reading Guide
Foundational Papers
Start with Northrup et al. (2013, 1465 citations) for core 2012 criteria and Krueger et al. (2013, 832 citations) for surveillance links, as they define major/minor features used in all subsequent work.
Recent Advances
Study Northrup et al. (2021, 630 citations) for updates and Tyburczy et al. (2015, 286 citations) for genetic refinements addressing no-mutation cases.
Core Methods
Consensus via expert panels; clinical major/minor features (tubers, nodules); genetic TSC1/TSC2 sequencing with deep coverage for mosaics.
How PapersFlow Helps You Research TSC Diagnostic Criteria and Consensus
Discover & Search
PapersFlow's Research Agent uses searchPapers with 'TSC diagnostic criteria consensus' to retrieve Northrup et al. (2013, 1465 citations), then citationGraph reveals forward citations like Northrup et al. (2021), and findSimilarPapers uncovers related surveillance guidelines (Krueger et al., 2013). exaSearch semantically matches queries on mosaic mutations to Tyburczy et al. (2015).
Analyze & Verify
Analysis Agent applies readPaperContent to extract criterion tables from Northrup et al. (2013), verifies changes via verifyResponse (CoVe) against 2021 updates, and uses runPythonAnalysis for statistical comparison of citation impacts or minor feature frequencies with GRADE grading for evidence strength in diagnostic shifts.
Synthesize & Write
Synthesis Agent detects gaps like post-2021 genetic criteria needs, flags contradictions between 2012 and 2021 minor features, and supports Writing Agent with latexEditText for criterion tables, latexSyncCitations for Northrup references, and latexCompile for guideline manuscripts. exportMermaid visualizes criteria evolution timelines.
Use Cases
"Compare prevalence of minor diagnostic criteria in TOSCA registry vs 2012 consensus"
Research Agent → searchPapers (TOSCA) → Analysis Agent → readPaperContent (Kingswood et al., 2017) + runPythonAnalysis (pandas crosstab of features vs criteria) → CSV export of prevalence stats
"Draft LaTeX table of 2012 vs 2021 TSC diagnostic changes"
Research Agent → citationGraph (Northrup 2013→2021) → Analysis Agent → readPaperContent → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → PDF table
"Find code for TSC genetic variant analysis from papers"
Research Agent → searchPapers ('TSC mutation analysis code') → Code Discovery → paperExtractUrls → paperFindGithubRepo (Tyburczy et al., 2015 supplements) → githubRepoInspect → runnable variant caller script
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TSC criteria papers, chaining searchPapers → citationGraph → GRADE grading for a structured consensus evolution report. DeepScan applies 7-step analysis with CoVe checkpoints to verify criterion changes between Northrup 2013 and 2021. Theorizer generates hypotheses on future criteria incorporating somatic mutations from Martin et al. (2017).
Frequently Asked Questions
What is the definition of TSC diagnostic criteria?
Definitive diagnosis requires either two major features or one major plus two minor features per 2012 consensus (Northrup et al., 2013). Genetic confirmation of TSC1/TSC2 mutation suffices alone.
What methods form consensus updates?
International panels review imaging, genetics, and epidemiology via Delphi process, as in 2012 and 2021 conferences (Northrup et al., 2013; Northrup et al., 2021).
What are key papers on TSC criteria?
Northrup et al. (2013, 1465 citations) sets 2012 standards; Northrup et al. (2021, 630 citations) provides updates; Krueger et al. (2013) links to surveillance.
What open problems exist in TSC diagnostics?
Detecting mosaic mutations affects 10-15% of cases (Tyburczy et al., 2015); standardizing minor criteria quantification; integrating multi-omics data.
Research Tuberous Sclerosis Complex Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching TSC Diagnostic Criteria and Consensus with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers